Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.9600
0.0192.02%
Last update: May 15, 8:40 AM
Aprea Therapeutics Inc Analyst Ratings
APRENASDAQ
Earnings: Q1 2026 Earnings were released on Wed May 13th, before the market open
Aprea Therapeutics Analyst Ratings and Price Targets | NASDAQ:APRE | Benzinga
Aprea Therapeutics Inc has a consensus price target of $4.07 based on the ratings of 3 analysts. The high is $6 issued by Wedbush on May 14, 2026. The low is $1.2 issued by HC Wainwright & Co. on March 31, 2026. The 3 most-recent analyst ratings were released by Wedbush, Oppenheimer, and Wedbush on May 14, 2026, May 7, 2026, and March 31, 2026, respectively. With an average price target of $6 between Wedbush, Oppenheimer, and Wedbush, there's an implied 559.20% upside for Aprea Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Aprea Therapeutics
Loading calendar...
FAQ
What is the target price for Aprea Therapeutics (APRE) stock?
The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by Wedbush on May 14, 2026. The analyst firm set a price target for $6.00 expecting APRE to rise to within 12 months (a possible 525.00% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by Wedbush, and Aprea Therapeutics maintained their outperform rating.
When was the last upgrade for Aprea Therapeutics (APRE)?
There is no last upgrade for Aprea Therapeutics
When was the last downgrade for Aprea Therapeutics (APRE)?
There is no last downgrade for Aprea Therapeutics.
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on May 14, 2026 so you should expect the next rating to be made available sometime around May 14, 2027.
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a maintained with a price target of $7.00 to $6.00. The current price Aprea Therapeutics (APRE) is trading at is $0.96, which is out of the analyst’s predicted range.
